GlassScriptPhysician profile
Martha E Quinton
NPI 1043734734
$6,368.06
in general payments reported to CMS, 2019-2025
25 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 96% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $524 · 2022: $865 · 2023: $1,309 · 2024: $1,766 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,978.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.15 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $762.63 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $685.54 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $570.73 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $558.75 | 2022-2025 | Rexulti, Vyepti |
| Janssen Pharmaceuticals, INC | $554.77 | 2022-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $447.61 | 2022-2025 | Rexulti |
| Eisai INC. | $409.77 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $334.94 | 2021-2025 | Nuplazid |
| Inspire Medical Systems, INC. | $114.65 | 2023 | Inspire |
| Sandoz INC. | $112.43 | 2025 | |
| Corium, LLC | $111.23 | 2022-2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $93.82 | 2023-2025 | Trintellix |
| Biogen, INC. | $93.12 | 2021 | |
| Biosense Webster, INC. | $79.50 | 2024 | Carto 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.49 | 2024-2025 | Amyvid, Kisunla |
| Merck Sharp & Dohme LLC | $54.17 | 2022 | |
| Alkermes, INC. | $41.48 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.96 | 2025 | Caplyta |
| Abbott Laboratories | $32.37 | 2023 | Proclaim |
| Saluda Medical Americas, INC. | $29.41 | 2024 | Evoke |
| Bioxcel Therapeutics, INC. | $22.04 | 2024 | Igalmi |
| Tms Neurohealth Centers INC. | $21.06 | 2025 | Tms Neurohealth Centers INC. |
| Supernus Pharmaceuticals, INC. | $19.30 | 2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Quinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.